OBJECTIVE: The purpose of this study was to assess the prevalence of @entity1817 ( @entity1817 ) @entity3018 in @entity1 with @entity0 and compare breast MRI and PET/CT for detection of @entity1817 @entity3018 . MATERIALS AND METHODS: This retrospective study included 90 @entity1 who underwent MRI and PET/CT before neoadjuvant chemotherapy for clinical stage IIA through IIIA disease. MRI and PET/CT examinations were read independently by two readers trained in breast imaging and nuclear medicine. All @entity1 underwent follow-up MRI at the end of chemotherapy, and 10 with @entity2495 IMNs underwent follow-up PET/CT. Histology was not obtained. @entity1 were considered to have @entity1817 @entity3018 when nodes seen on MRI or having standardized uptake value (SUV) greater than mediastinal blood pool decreased in either size or SUV (or both) after treatment. Features including lymphovascular invasion, @entity5 quadrant(s), and axillary @entity3018 were compared between presence and absence of @entity1817 @entity3018 using Fisher's exact test. Prevalence was determined on the basis of the percentage of @entity1 with @entity1817 @entity3018 by either modality. The McNemar test compared the prevalence of @entity1817 @entity3018 on MRI to its prevalence on PET/CT. RESULTS: Prevalence of @entity1817 @entity3018 was 16% (14/90) by MRI and 14% (13/90) by PET/CT (p = 0.317). After chemotherapy, @entity1817 @entity3018 resolved in 12 of 14 @entity1 (86%). In two @entity1 with poor responses in @entity5 , @entity1817 @entity3018 persisted, and both @entity1 developed @entity3 within 6 months. At 3 years, survival was significantly worse in @entity1 with @entity1817 @entity3018 than in those without (85.7% vs 53.3%, respectively; p = 0.009). CONCLUSION: In @entity1 with @entity0 receiving neoadjuvant chemo-therapy, prevalence of @entity1817 @entity3018 was 16%, equally detected by breast MRI and PET/CT. Identification of @entity1817 @entity3018 may affect treatment and provides prognostic information.

Detection of Internal Mammary Adenopathy in XXXX With @entity0 by PET/CT and MRI.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women'] @entity3018 :: ('MESH:D009377', 'Disease') :: ['adenopathy'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'advanced breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors'] @entity1817 :: ('MESH:D012804', 'Disease') :: ['IMN', 'internal mammary node'] @entity2495 :: ('MESH:C565498', 'Disease') :: ['hypermetabolic'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']
@entity1 :: (9606,Species) :: ['Patients']
